Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants with Glioblastoma
- Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma
- Karnofsky performance status (KPS) >= 60
- Patients must have recovered from the effects of surgery per treating physician’s judgment; there must be a minimum of 21 days from the day of surgery to the day of protocol treatment; for core or needle biopsy, a minimum of 14 days must have elapsed prior to the day of protocol treatment
- Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
- Platelets >= 100,000 cells/mm^3
- Hemoglobin >= 9.0 g/dl
- Creatinine clearance > 30 mL/min
- Bilirubin < 2.0 mg/dL
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x upper limit of normal range
- Women of childbearing potential must have a negative beta-human chorionic gonadotropin (HCG) pregnancy test documented within 14 days prior to registration
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after last dose of temozolomide
- Is able to have magnetic resonance imaging (MRI) with contrast of the brain
- All subjects must be able to comprehend and sign a written informed consent document; if the subject can comprehend the informed consent but is unable to sign, a legally authorized representative (LAR) may sign the written informed consent document
- Infratentorial disease (defined as glioblastoma [GBM] derived from cerebellum or brainstem)
- Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias
- A skull defect (such as, missing bone with no replacement)
- Women of childbearing potential who are pregnant or breastfeeding
- Evidence of increased intracranial pressure (midline shift > 5 mm, clinically significant papilledema)
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study, in the opinion of the investigator
- Prior radiation treatment to the brain
- Prior treatment with temozolomide
- Known hypersensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes
- Known active collagen vascular disease
- Patients with non-healing surgical incisions or wounds on the scalp
I. To evaluate the safety and toxicity of combination chemoradiotherapy with NovoTTF-100A device (Optune) treatment in newly diagnosed glioblastoma.
I. To determine the median progression-free survival of patients with newly diagnosed glioblastoma treated with radiotherapy with concurrent and adjuvant temozolomide plus Optune.
II. To evaluate the median overall survival, 1-year overall survival, and event-free survival.
III. To evaluate the level of circulating tumor deoxyribonucleic acid (DNA) in glioblastoma patient serum during treatment.
IV. To evaluate the quality of life of patients treated with radiotherapy with concurrent and adjuvant temozolomide plus Optune.
Participants receive temozolomide orally (PO) once daily (QD) starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-100A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up every 3 months for up to 2 years.
Trial Phase Phase O
Trial Type Treatment
Thomas Jefferson University Hospital
- Primary ID 17P.346
- Secondary IDs NCI-2018-00357
- Clinicaltrials.gov ID NCT03477110